Bivalirudin - Revision history

Danbot: Switch SMW query from broadtable to table format for better layout with TOC

2026-03-20T21:58:20Z

Switch SMW query from broadtable to table format for better layout with TOC

← Older revision		Revision as of 21:58, 20 March 2026
Line 62:		Line 62:
	\|?Has Route=Route		\|?Has Route=Route
	\|?Has Population=Population		\|?Has Population=Population
	\|format=~~broadtable~~		\|format=table
	\|headers=plain		\|headers=plain
	\|mainlabel=-		\|mainlabel=-

Danbot: Fix SMW query: replace link=subject with mainlabel=- to fix broken subobject fragment links

2026-03-20T17:25:56Z

Fix SMW query: replace link=subject with mainlabel=- to fix broken subobject fragment links

← Older revision		Revision as of 17:25, 20 March 2026
Line 64:		Line 64:
	\|format=broadtable		\|format=broadtable
	\|headers=plain		\|headers=plain
	\|~~link~~=~~subject~~		\|mainlabel=-
	\|sort=Has Indication		\|sort=Has Indication
	\|limit=50		\|limit=50

Danbot: Add dynamic SMW Indications by Condition table (auto-populated from disease pages via MedicationDose template)

2026-03-20T16:44:06Z

Add dynamic SMW Indications by Condition table (auto-populated from disease pages via MedicationDose template)

← Older revision		Revision as of 16:44, 20 March 2026
Line 51:		Line 51:

	==Comments==		==Comments==


			==Indications by Condition==
			''The following table is automatically generated from disease/condition pages across WikEM.''

			{{#ask:[[Has DrugName::Bivalirudin]]
			\|?Has Indication=Indication
			\|?Has Dose=Dose
			\|?Has Context=Context
			\|?Has Route=Route
			\|?Has Population=Population
			\|format=broadtable
			\|headers=plain
			\|link=subject
			\|sort=Has Indication
			\|limit=50
			}}

	==See Also==		==See Also==

Elcatracho: /* See Also */

2021-03-08T16:23:27Z

Fletc151: /* References */

2019-06-10T13:34:34Z

References

@@ Line 56: / Line 56: @@
 ==References==
 <references/>
 [[Category:Pharmacology]]

Humanguy: /* Pharmacology */ edited metabolism, excretion

2017-10-11T23:06:07Z

Pharmacology: edited metabolism, excretion

← Older revision		Revision as of 23:06, 11 October 2017
Line 43:		Line 43:

	==Pharmacology==		==Pharmacology==
	*Half-life: ~~25min~~		*Half-life: 25 min
	*Metabolism: ~~Renal~~		*Metabolism: Blood proteases
	*Excretion:		*Excretion: Renal

	==Mechanism of Action==		==Mechanism of Action==

Humanguy: edited dosage forms, strengths, trade names

2017-10-11T23:05:02Z

edited dosage forms, strengths, trade names

← Older revision		Revision as of 23:05, 11 October 2017
Line 1:		Line 1:
	==Administration==		==Administration==
	*Type: [[Anticoagulant]] (Direct thrombin inhibitor)		*Type: [[Anticoagulant]] (Direct thrombin inhibitor)
	*Dosage Forms:		*Dosage Forms: powder for injection
			*Dosage Strengths: 250mg
	*Routes of Administration: IV		*Routes of Administration: IV
	*Common Trade Names: Angiomax		*Common Trade Names: Angiomax, Angiox

	==Adult Dosing==		==Adult Dosing==

ClaireLewis: Created page with "==Administration== Type: Anticoagulant (Direct thrombin inhibitor) Dosage Forms: Routes of Administration: IV Common Trade Names: Angiomax ==Adult Dosing== *Acute MI,..."

2016-11-12T23:12:25Z

Created page with "==Administration== *Type: Anticoagulant (Direct thrombin inhibitor) *Dosage Forms: *Routes of Administration: IV *Common Trade Names: Angiomax ==Adult Dosing== *Acute MI,..."

New page

==Administration==
*Type: [[Anticoagulant]] (Direct thrombin inhibitor)
*Dosage Forms:
*Routes of Administration: IV
*Common Trade Names: Angiomax

==Adult Dosing==
*Acute MI, adjunct to thrombolysis: 0.25 mg/kg IV bolus + 0.5 mg/kg/hr x 12h, then 0.25 mg/kg/hr x 36h
*PCI Thrombosis prophylaxis: 0.75 mg/kg IV bolus + 1.75 mg/kg/hr IV infusion during procedure + 0.2mg/kg/hr x 4-20h after procedure
*Unstable angina/NSTEMI: 0.1 mg/kg IV bolus + 0.25 mg/kg/hour IV infusion

==Pediatric Dosing==
''Safety/efficacy not established''

==Special Populations==
*[[Drug Ratings in Pregnancy|Pregnancy Rating]]: B
*[[Lactation risk categories|Lactation risk]]: Infant risk cannot be ruled out
*Renal dosing: no adjustment in bolus dosing
**CrCl 30-59 mL/min: no adjustment in infusion or bolus dose
**CrCl <30: consider reducing infusion to 1 mg/kg/hr
**Hemodialysis: Reduce infusion rate to 0.25 mg/kg/hr
*Hepatic dosing:

==Contraindications==
*Allergy to class/drug
*Active major bleeding

==Adverse Reactions==
===Serious===
*Major bleeding: retroperitoneal, intracranial hemorrhage
*Coronary artery stent thrombosis, ventricular fibrillation
*Thrombosis
*Cerebral ischemia
*Peripheral facial palsy
*Oliguria, renal failure
*Sepsis
===Common===
*Hypotension
*Minor bleeding
*Nausea
*Headache, backache, pain

==Pharmacology==
*Half-life: 25min
*Metabolism: Renal
*Excretion:

==Mechanism of Action==
*Binds to and inhibits thrombin

==Comments==

==See Also==
*[[Anticoagulant reversal for life-threatening bleeds]]

==References==
<references/>
[[Category:Pharmacology]]

← Older revision		Revision as of 16:23, 8 March 2021
Line 53:		Line 53:

	==See Also==		==See Also==
			*[[Coagulopathy (main)]]
	*[[Anticoagulant reversal for life-threatening bleeds]]		*[[Anticoagulant reversal for life-threatening bleeds]]